News

TOKYO, November 5, 2018  - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that the company’s mid-to-long term greenhouse gas (GHG) emission reduction targets to achieve the “2 degrees Celsius target” of the Paris Agreement were approved by the Science Based Targets (SBT) Initiative1 as a science-based international initiative. As a company...

TOKYO, October 31, 2018  - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that construction and renovation of new facilities for the research, development and manufacture of new drugs using new Modality/Technology has begun in Toyama and Tsukuba, Japan as well as Massachusetts, United States. Astellas is focused on creating innovative...

TOKYO and San Francisco, October 30, 2018  - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff, “FibroGen”) today announced the presentation of data from two Japanese Phase 3 studies (1517-CL-0302 and 1517-CL-0307) of roxadustat (development code: ASP1517/FG-4592) for the treatment of anemia associated with...

Results from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs. 14.7 months for men who received placebo plus ADT1 TOKYO, October 29, 2018  - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the European Commission (EC) has approved a new indication...